Dyne Therapeutics, Inc. (NASDAQ:DYN) Shares Sold by Fcpm Iii Services B.V.

Fcpm Iii Services B.V. lessened its stake in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 8.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,462,846 shares of the company's stock after selling 491,223 shares during the period. Dyne Therapeutics makes up about 21.8% of Fcpm Iii Services B.V.'s holdings, making the stock its 2nd biggest holding. Fcpm Iii Services B.V. owned 5.37% of Dyne Therapeutics worth $128,705,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also bought and sold shares of the company. Frontier Capital Management Co. LLC bought a new stake in Dyne Therapeutics during the 4th quarter valued at $7,022,000. Deutsche Bank AG raised its holdings in Dyne Therapeutics by 51.4% during the 4th quarter. Deutsche Bank AG now owns 70,961 shares of the company's stock valued at $1,672,000 after buying an additional 24,104 shares during the last quarter. D. E. Shaw & Co. Inc. raised its holdings in Dyne Therapeutics by 83.1% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 133,772 shares of the company's stock worth $3,152,000 after purchasing an additional 60,732 shares in the last quarter. Crestline Management LP raised its holdings in Dyne Therapeutics by 57.0% in the 4th quarter. Crestline Management LP now owns 184,818 shares of the company's stock worth $4,354,000 after purchasing an additional 67,137 shares in the last quarter. Finally, Cubist Systematic Strategies LLC bought a new position in Dyne Therapeutics in the 4th quarter worth $2,805,000. Hedge funds and other institutional investors own 96.68% of the company's stock.

Dyne Therapeutics Stock Down 5.5%

DYN stock traded down $0.67 during mid-day trading on Wednesday, hitting $11.43. 1,163,549 shares of the company were exchanged, compared to its average volume of 1,666,437. The firm has a market capitalization of $1.30 billion, a P/E ratio of -3.21 and a beta of 1.19. The business has a fifty day simple moving average of $10.37 and a 200-day simple moving average of $17.81. Dyne Therapeutics, Inc. has a 12-month low of $6.36 and a 12-month high of $47.45.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($1.05) earnings per share for the quarter, missing analysts' consensus estimates of ($0.88) by ($0.17). Research analysts predict that Dyne Therapeutics, Inc. will post -3.44 EPS for the current year.

Insider Activity at Dyne Therapeutics

In other Dyne Therapeutics news, insider Oxana Beskrovnaya sold 2,598 shares of the stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $13.95, for a total value of $36,242.10. Following the completion of the sale, the insider now owns 199,087 shares of the company's stock, valued at $2,777,263.65. This trade represents a 1.29% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In the last quarter, insiders sold 6,237 shares of company stock valued at $77,760. 14.14% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

DYN has been the subject of several research reports. Royal Bank of Canada restated an "outperform" rating and issued a $45.00 price objective on shares of Dyne Therapeutics in a report on Tuesday, January 14th. Piper Sandler cut their price objective on shares of Dyne Therapeutics from $53.00 to $48.00 and set an "overweight" rating on the stock in a research report on Friday, February 28th. JPMorgan Chase & Co. cut their price objective on shares of Dyne Therapeutics from $18.00 to $17.00 and set a "neutral" rating on the stock in a research report on Friday, March 21st. Chardan Capital reissued a "buy" rating and set a $50.00 price objective on shares of Dyne Therapeutics in a research report on Friday, May 9th. Finally, Scotiabank began coverage on shares of Dyne Therapeutics in a research report on Friday, March 7th. They set a "sector outperform" rating and a $50.00 price objective on the stock. One analyst has rated the stock with a sell rating, one has issued a hold rating, twelve have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $46.85.

Dyne Therapeutics Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.